Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in:

13-02-2024 | COVID-19 | Review Article

Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers

Authors: Rasoul Ebrahimi, Fatemeh Nasri, Tahereh Kalantari

Published in: Annals of Hematology | Issue 6/2024

Login to get access

Abstract

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as 2019-nCoV. Numerous cellular and biochemical issues arise after COVID-19 infection. The severe inflammation that is caused by a number of cytokines appears to be one of the key hallmarks of COVID-19. Additionally, people with severe COVID-19 have coagulopathy and fulminant thrombotic events. We briefly reviewed the COVID-19 disease at the beginning of this paper. The inflammation and coagulation markers and their alterations in COVID-19 illness are briefly discussed in the parts that follow. Next, we talked about NETosis, which is a crucial relationship between coagulation and inflammation. In the end, we mentioned the two-way relationship between inflammation and coagulation, as well as the factors involved in it. We suggest that inflammation and coagulation are integrated systems in COVID-19 that act on each other in such a way that not only inflammation can activate coagulation but also coagulation can activate inflammation.
Literature
1.
2.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506PubMedPubMedCentralCrossRef
3.
4.
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 323(13):1239–1242PubMedCrossRef
5.
Aktas G (2020) A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS Cov-2 infection. Exp Biomed Res 3(4):293–311CrossRef
6.
Aktas G, Balci B, Yilmaz S, Bardak H, Duman TT, Civil C (2022) Characteristics of Covid-19 infection with the original SARS-Cov-2 virus and other variants: a comparative review. J Bionic Mem 2(3):96–112
7.
8.
Khalid A, Ali Jaffar M, Khan T, Abbas Lail R, Ali S, Aktas G et al (2021) Hematological and biochemical parameters as diagnostic and prognostic markers in SARS-COV-2 infected patients of Pakistan: a retrospective comparative analysis. Hematology 26(1):529–542PubMedCrossRef
9.
Aktas G (2021) Hematological predictors of novel coronavirus infection. Rev Assoc Med Bras 67:1–2CrossRef
10.
Fei Y, Tang N, Liu H, Cao W (2020) Coagulation dysfunctiona hallmark in COVID-19. Arch Pathol Lab Med 144(10):1223–1229PubMedCrossRef
11.
Hadid T, Kafri Z, Al-Katib A (2021) Coagulation and anticoagulation in COVID-19. Blood Rev 47:100761PubMedCrossRef
12.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T (2020) Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 57(6):389–399PubMedCrossRef
13.
14.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 183(6):1735PubMedPubMedCentralCrossRef
15.
Lei J, Kusov Y, Hilgenfeld R (2018) Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antivir Res 149:58–74PubMedCrossRef
16.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273PubMedPubMedCentralCrossRef
17.
Liew FY, Girard JP, Turnquist HR (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16(11):676–689PubMedCrossRef
18.
Cayrol C, Girard JP (2018) Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev 281(1):154–168PubMedCrossRef
19.
20.
Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M (2019) IL-33 Mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front Immunol 10:692PubMedPubMedCentralCrossRef
21.
Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD et al (2020) Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 8(8):750–752PubMedPubMedCentralCrossRef
22.
Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282(36):26369–26380PubMedCrossRef
23.
24.
Zeng Z, Hong X-Y, Zhou H, Liao F-L, Guo S, Li Y et al (2020) Serum soluble ST2 as a novel biomarker reflecting inflammatory status and disease severity in patients with COVID-19. Available at SSRN 3594550
25.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(7):811–818PubMedCrossRef
26.
Zeng Z, Hong XY, Li Y, Chen W, Ye G, Li Y, Luo Y (2020) Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med 14(17):1619–1629PubMedCrossRef
27.
Baggiolini M, Walz A, Kunkel SL (1989) Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84(4):1045–1049PubMedPubMedCentralCrossRef
28.
Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M (1991) Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med 173(3):771–774PubMedCrossRef
29.
Ma A, Zhang L, Ye X, Chen J, Yu J, Zhuang L et al (2021) High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19. Front Immunol 12:626235PubMedPubMedCentralCrossRef
30.
Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y et al (2020) IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A 117(36):22351–22356PubMedPubMedCentralCrossRef
31.
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5(11).
32.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499–511PubMedCrossRef
33.
34.
Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3):363–369PubMedCrossRef
35.
Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D (1995) Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann N Y Acad Sci 762:102–107PubMedCrossRef
36.
Calabró P, Willerson JT, Yeh ET (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108(16):1930–1932PubMedCrossRef
37.
38.
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS (2021) C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 42(23):2270–2279PubMedPubMedCentralCrossRef
39.
Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B (2020) C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 14:1753466620937175PubMedPubMedCentralCrossRef
40.
Quinlan GJ, Martin GS, Evans TW (2005) Albumin: biochemical properties and therapeutic potential. Hepatology 41(6):1211–1219PubMedCrossRef
41.
42.
43.
Paliogiannis P, Mangoni AA, Cangemi M, Fois AG, Carru C, Zinellu A (2021) Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis. Clin Exp Med 21(3):343–354PubMedPubMedCentralCrossRef
44.
Bansal A, Prasad JB (2022) Liver profile in COVID-19: a meta-analysis. Z Gesundh Wiss 30(1):253–258PubMedCrossRef
45.
Parohan M, Yaghoubi S, Seraji A (2020) Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies. Hepatol Res 50(8):924–935PubMedPubMedCentralCrossRef
46.
Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J et al (2020) Clinical characteristics of 82 cases of death from COVID-19. PLoS One 15(7):e0235458
47.
Torun A, Çakırca TD, Çakırca G (1992) Portakal RD (2021) The value of C-reactive protein/albumin, fibrinogen/albumin, and neutrophil/lymphocyte ratios in predicting the severity of CoVID-19. Rev Assoc Med Bras 67(3):431–436CrossRef
48.
Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY et al (2018) The C-reactive protein/albumin ratio as a predictor of mortality in critically ill patients. J Clin Med 7(10):333PubMedPubMedCentralCrossRef
49.
Kalabin A, Mani VR, Valdivieso SC, Donaldson B (2021) Does C reactive protein/albumin ratio have prognostic value in patients with COVID-19. J Infect Dev Ctries 15(08):1086–1093PubMedCrossRef
50.
Karagoz I, Ozer B, Ital I, Turkoglu M, Disikirik A, Ozer S (2023) C-reactive protein-to-serum albumin ratio as a marker of prognosis in adult intensive care population. Bratisl Lek Listy 124(4):277–279
51.
52.
Bilgin S, Kurtkulagi O, Tel BMA, Duman TT, Kahveci G, Khalid A, Aktas G (2021) Does C-reactive protein to serum albumin ratio correlate with diabetic nephropathy in patients with type 2 diabetes mellitus? The CARE TIME study. Prim Care Diabetes 15(6):1071–1074PubMedCrossRef
53.
Xie Q, Zhou Y, Xu Z, Yang Y, Kuang D, You H et al (2011) The ratio of CRP to prealbumin levels predict mortality in patients with hospital-acquired acute kidney injury. BMC Nephrol 12:30PubMedPubMedCentralCrossRef
54.
Kalyon S, Gültop F, Şimşek F, Adaş M (2021) Relationships of the neutrophil-lymphocyte and CRP-albumin ratios with the duration of hospitalization and fatality in geriatric patients with COVID-19. J Int Med Res 49(9):3000605211046112PubMedCrossRef
55.
Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K (1997) Procalcitonin--a new indicator of the systemic response to severe infections. Infection 25(6):329–334PubMedPubMedCentralCrossRef
56.
Organization WH (2014) Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland, p 2017
57.
Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ et al (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62(4):337–340PubMedPubMedCentralCrossRef
58.
Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K (1999) Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 37(8):789–797PubMedCrossRef
59.
Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, Liu ZS (2020) Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 16(3):251–259PubMedPubMedCentralCrossRef
60.
Chen X, Yang Y, Huang M, Liu L, Zhang X, Xu J et al (2020) Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center. J Med Virol 92(9):1572–1579PubMedCrossRef
61.
Yunus I, Fasih A, Wang Y (2018) The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLoS One 13(11):e0206527PubMedPubMedCentralCrossRef
62.
Wolfisberg S, Gregoriano C, Schuetz P (2022) Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci 59(1):54–65PubMedCrossRef
63.
64.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509–1518PubMedPubMedCentralCrossRef
65.
Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M et al (2020) Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 146(1):128–36.e4PubMedPubMedCentralCrossRef
66.
Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS (2020) IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev 53:13–24PubMedPubMedCentralCrossRef
67.
Abbasifard M, Khorramdelazad H (2020) The bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci 257:118097PubMedPubMedCentralCrossRef
68.
Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A et al (2021) The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol 17(6):601–618PubMedCrossRef
69.
Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y et al (2020) Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis 71(8):1937–1942PubMedCrossRef
70.
Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J et al (2020) The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med 12(7):e12421PubMedPubMedCentralCrossRef
71.
Saraiva M, Vieira P, O'Garra A (2020) Biology and therapeutic potential of interleukin-10. J Exp Med 217(1):e20190418PubMedCrossRef
72.
Moore KW, de Waal MR, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765PubMedCrossRef
73.
Lu L, Zhang H, Dauphars DJ, He YW (2021) A potential role of interleukin 10 in COVID-19 Pathogenesis. Trends Immunol 42(1):3–5PubMedCrossRef
74.
75.
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W et al (2020) Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 9(1):1123–1130PubMedPubMedCentralCrossRef
76.
Dhar SK, Vishnupriyan K, Damodar S, Gujar S, Das M (2021) IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon 7(2):e06155PubMedPubMedCentralCrossRef
77.
Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J et al (2020) Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight 5(13)
78.
Weitz JI, Fredenburgh JC, Eikelboom JW (2017) A test in context: D-dimer. J Am Coll Cardiol 70(19):2411–2420PubMedCrossRef
79.
Adam SS, Key NS, Greenberg CS (2009) D-dimer antigen: current concepts and future prospects. Blood 113(13):2878–2887PubMedCrossRef
80.
Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Büller HR et al (2014) D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 12(4):479–487PubMedCrossRef
81.
Rao KM, Pieper CS, Currie MS, Cohen HJ (1994) Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 102(6):802–805PubMedCrossRef
82.
Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS (2002) D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121(4):1262–1268PubMedCrossRef
83.
Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM (2001) C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 21(4):603–610
84.
Xu Y, Qian Y, Gu Q, Tang J (2020) Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 32(5):559–563PubMed
85.
Moreno G, Carbonell R, Bodí M, Rodríguez A (2021) Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva (Engl Ed) 45(1):42–55PubMedCrossRef
86.
87.
88.
Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145(1):24–33PubMedCrossRef
89.
Han H, Yang L, Liu R, Liu F, Wu KL, Li J et al (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 58(7):1116–1120PubMedCrossRef
90.
Giannis D, Ziogas IA, Gianni P (2020) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 127:104362PubMedPubMedCentralCrossRef
91.
Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, Resta M et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18(7):1747–1751PubMedPubMedCentralCrossRef
92.
Morrissey JH, Fakhrai H, Edgington TS (1987) Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 50(1):129–135PubMedCrossRef
93.
Morrissey JH (2001) Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 86(1):66–74PubMed
94.
Bauer W, Galtung N, Neuwinger N, Kaufner L, Langer E, Somasundaram R et al (2021) A Matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department. TH Open 5(1):e43–e55PubMedPubMedCentralCrossRef
95.
Camerer E, Huang W, Coughlin SR (2000) Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 97(10):5255–5260PubMedPubMedCentralCrossRef
96.
97.
Foley JH, Conway EM (2016) Cross talk pathways between coagulation and inflammation. Circ Res 118(9):1392–1408PubMedCrossRef
98.
Eslamifar Z, Behzadifard M, Soleimani M, Behzadifard S (2020) Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor. Thromb J 18(1):38PubMedPubMedCentralCrossRef
99.
Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J et al (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400):1953–1958PubMedCrossRef
100.
Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR et al (2020) Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 136(11):1330–1341PubMedCrossRef
101.
Rosell A, Havervall S, von Meijenfeldt F, Hisada Y, Aguilera K, Grover SP et al (2021) Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler Thromb Vasc Biol 41(2):878–882PubMedCrossRef
102.
Subrahmanian S, Borczuk A, Salvatore S, Fung KM, Merrill JT, Laurence J, Ahamed J (2021) Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J Thromb Haemost 19(9):2268–2274PubMedCrossRef
103.
Hassan MI, Saxena A, Ahmad F (2012) Structure and function of von Willebrand factor. Blood Coagul Fibrinolysis 23(1):11–22PubMedCrossRef
104.
Li S, Wang Z, Liao Y, Zhang W, Shi Q, Yan R et al (2010) The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 8(2):341–350PubMedCrossRef
105.
Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324(5932):1330–1334PubMedPubMedCentralCrossRef
106.
Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W et al (2008) Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 93(1):137–140PubMedCrossRef
107.
108.
van Breevoort D, van Agtmaal EL, Dragt BS, Gebbinck JK, Dienava-Verdoold I, Kragt A et al (2012) Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. J Proteome Res 11(5):2925–2936PubMedCrossRef
109.
Kawecki C, Lenting PJ, Denis CV (2017) von Willebrand factor and inflammation. J Thromb Haemost 15(7):1285–1294PubMedCrossRef
110.
Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M (2022) High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med 22(3):347–357PubMedCrossRef
111.
Aird WC (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101(10):3765–3777PubMedCrossRef
112.
Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D (2020) Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 15(5):861–863PubMedPubMedCentralCrossRef
113.
Xu J, Esmon NL, Esmon CT (1999) Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 274(10):6704–6710PubMedCrossRef
114.
Walker FJ (1980) Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 255(12):5521–5524PubMedCrossRef
115.
Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109(8):3161–3172PubMedCrossRef
116.
Oto J, Fernandez-Pardo A, Miralles M, Plana E, Espana F, Navarro S, Medina P (2020) Activated protein C assays: a review. Clin Chim Acta 502:227–232PubMedCrossRef
117.
Mosnier LO, Griffin JH (2006) Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci 11:2381–2399
118.
119.
Healy LD, Puy C, Fernández JA, Mitrugno A, Keshari RS, Taku NA et al (2017) Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. J Biol Chem 292(21):8616–8629PubMedPubMedCentralCrossRef
120.
121.
Mazzeffi MA, Chow JH, Tanaka K (2021) COVID-19 associated hypercoagulability: manifestations, mechanisms, and management. Shock 55(4):465–471PubMedCrossRef
122.
Stanne TM, Pedersen A, Gisslén M, Jern C (2021) Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19. Thromb Res 204:13–15PubMedPubMedCentralCrossRef
123.
Stoichitoiu LE, Pinte L, Balea MI, Nedelcu V, Badea C, Baicus C (2020) Anticoagulant protein S in COVID-19: low activity, and associated with outcome. Rom J Intern Med 58(4):251–258PubMed
124.
Hanchard J, Capó-Vélez CM, Deusch K, Lidington D, Bolz SS (2020) Stabilizing cellular barriers: raising the shields against COVID-19. Front Endocrinol (Lausanne) 11:583006PubMedCrossRef
125.
Pepper MS (2001) Extracellular proteolysis and angiogenesis. Thromb Haemost 86(1):346–355PubMed
126.
Levin EG, Marzec U, Anderson J, Harker LA (1984) Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 74(6):1988–1995PubMedPubMedCentralCrossRef
127.
Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ et al (2003) Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278(51):51059–51067PubMedCrossRef
128.
Kolev K, Machovich R (2003) Molecular and cellular modulation of fibrinolysis. Thromb Haemost 89(4):610–621PubMedCrossRef
129.
Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185(9):5628–5636PubMedCrossRef
130.
Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847PubMedPubMedCentralCrossRef
131.
132.
Kam YW, Okumura Y, Kido H, Ng LF, Bruzzone R, Altmeyer R (2009) Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One 4(11):e7870PubMedPubMedCentralCrossRef
133.
134.
Gacche RN, Gacche RA, Chen J, Li H, Li G (2021) Predictors of morbidity and mortality in COVID-19. Eur Rev Med Pharmacol Sci 25(3):1684–1707PubMed
135.
Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL et al (2006) Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thromb Haemost 96(1):100–101PubMed
136.
Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW (2020) An aberrant STAT pathway is central to COVID-19. Cell Death Differ 27(12):3209–3225PubMedCrossRef
137.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532–1535PubMedCrossRef
138.
Li B, Liu Y, Hu T, Zhang Y, Zhang C, Li T et al (2019) Neutrophil extracellular traps enhance procoagulant activity in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol 145(7):1695–1707PubMedCrossRef
139.
Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V et al (2007) Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176(2):231–241PubMedPubMedCentralCrossRef
140.
Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191(3):677–691PubMedPubMedCentralCrossRef
141.
Björnsdottir H, Welin A, Michaëlsson E, Osla V, Berg S, Christenson K et al (2015) Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic Biol Med 89:1024–1035PubMedCrossRef
142.
Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC (2014) Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 34(9):1977–1984PubMedCrossRef
143.
Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT (2011) Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 9(9):1795–1803PubMedCrossRef
144.
145.
Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I et al (1992) Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 90(6):2565–2573PubMedPubMedCentralCrossRef
146.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659–1665PubMed
147.
Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U et al (2005) Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 385(Pt 3):831–838PubMedPubMedCentralCrossRef
148.
Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P et al (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104(15):6388–6393PubMedPubMedCentralCrossRef
149.
Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N et al (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26(1):1–43PubMedCrossRef
150.
Strukova S (2006) Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front Biosci 11:59–80PubMedCrossRef
151.
Tunjungputri RN, Li Y, de Groot PG, Dinarello CA, Smeekens SP, Jaeger M et al (2018) The inter-relationship of platelets with interleukin-1β-mediated inflammation in humans. Thromb Haemost 118(12):2112–2125PubMedCrossRef
152.
Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC et al (2021) Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev 20(3):102763PubMedCrossRef
153.
José RJ, Williams AE, Chambers RC (2014) Proteinase-activated receptors in fibroproliferative lung disease. Thorax 69(2):190–192PubMedCrossRef
154.
Levi M, Keller TT, van Gorp E, ten Cate H (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60(1):26–39PubMedCrossRef
155.
156.
Li G, Chen X, Xu A (2003) Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 349(5):508–509PubMedCrossRef
157.
158.
Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18(7):1743–1746PubMedPubMedCentralCrossRef
Metadata
Title
Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers
Authors
Rasoul Ebrahimi
Fatemeh Nasri
Tahereh Kalantari
Publication date
13-02-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05630-1

Other articles of this Issue 6/2024

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis

Therapeutic progress in relapsed/refractory multiple myeloma

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects

Diagnosing aceruloplasminemia: navigating through red herrings

Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits